和元生物技术（上海）股份有限公司 董事会薪酬与考核委员会关于公司 2025 年限制性股票激励 计划首次授予激励对象名单的审核意见(截止授予日) 和元生物技术（上海）股份有限公司（以下简称"公司"）董事会薪酬与考 核委员会依据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共 和国证券法》(以下简称"《证券法》")、《上市公司股权激励管理办法》(以下 简称"《管理办法》")、《上海证券交易所科创板股票上市规则》(以下简称"《科 创板上市规则》")、《科创板上市公司自律监管指南第4号——股权激励信息披 露》等相关法律、法规及规范性文件和《和元生物技术（上海）股份有限公司章 程》(以下简称"《公司章程》")的有关规定,对公司2025年限制性股票激励计 划(以下简称"本次激励计划")首次授予激励对象名单（截止授予日）进行了核 查,发表核查意见如下： 1、本次激励计划所确定的激励对象不存在《管理办法》规定的不得成为激 励对象的下列情形： （1）最近12个月内被证券交易所认定为不适当人选； （3）最近12个月内因重大违法违规行为被中国证监会及其派出机构行政处 罚或者采取市场禁入措施； （4）具有《公司法》规 ...

证券代码：688238 证券简称：和元生物 公告编号：2025-056 和元生物技术（上海）股份有限公司 关于向 2025 年限制性股票激励计划激励对象 首次授予限制性股票的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、限制性股票授予情况 （一）本次限制性股票授予已履行的决策程序和信息披露情况 1、2025 年 6 月 27 日，公司第四届董事会第一次会议审议通过了《关于公 司<2025 年限制性股票激励计划（草案）>及其摘要的议案》《关于公司<2025 年 限制性股票激励计划实施考核管理办法>的议案》《关于公司 2025 年限制性股票 激励计划首次授予的激励对象名单的议案》《关于提请股东会授权董事会办理股 权激励相关事宜的议案》。董事会薪酬与考核委员会对公司 2025 年限制性股票激 励计划（草案）进行了核实，并出具了相关核查意见。2025 年 6 月 28 日，公司 在上海证券交易所网站（www.sse.com.cn）披露了《和元生物技术（上海）股份 有限公司 2025 年限制性股票激励计划 ...

和元生物技术（上海）股份有限公司 2025 年限制性股票激励计划首次授予激励对象名单 (截止授予日) | | | | 获授的限制 | 获授限制 性股票占 | 获授限制 性股票占 | | --- | --- | --- | --- | --- | --- | | 姓名 | 国籍 | 职务 | 性股票数量 | | | | | | | （股） | 授予总量 | 当前总股 | | | | | | 的比例 | 本比例 | | 一、首次授予部分 | | | | | | | 1、董事、高级管理人员、核心技术人员 | | | | | | | 潘俊屹 | 中国 | 董事、副总经理 | 190,000 | 5.07% | 0.03% | | 王耀 | 中国 | 副总经理 | 190,000 | 5.07% | 0.03% | | 栾振国 | 中国 | 副总经理、财务负责人 | 120,000 | 3.20% | 0.02% | | 吴钦斌 | 中国 | 副总经理 | 90,000 | 2.40% | 0.01% | | 宋思杰 | 中国 | 职工代表董事、骨干人员 | 45,000 | 1.20% | 0.01% | | 刘素丽 ...

上海市金茂律师事务所 关于 和元生物技术（上海）股份有限公司 2025 年限制性股票激励计划 首次授予事项 Jin Mao Law Firm 147 程 E 消 同行 Effin 40th Floor, Bund Center, 222 East Yan An Road, Shanghai 200002, P.R.China 中国上海延安东路 222 号外滩中心 40 楼 200002 Tel/电话:(8621)6249 6040 Fax/传真:(8621) 6248 2266 Website/网址:www.jinmao.com.cn 上海市金茂律师事务所 关于和元生物技术(上海)股份有限公司 2025 年限制性股票激励计划首次授予事项之 之 法律意见书 二〇二五年七月 | | | | 目 求 … | | --- | | 第一节 释 义 | | 第二节 引 言 | | 第三节 正 文 | | 1 本次授予的批准与授权 . | | 二、 本次授予的具体情况 | | 11 J 结论意见 . | l 法律意见书 致:和元生物技术(上海)股份有限公司 敬启者: 根据上海市金茂律师事务所(以下简称"本所")与和元生物技 ...

经与会董事审议表决，形成的会议决议如下： 证券代码：688238 证券简称：和元生物 公告编号：2025-055 和元生物技术（上海）股份有限公司 第四届董事会第二次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 和元生物技术（上海）股份有限公司（以下简称"公司"）第四届董事会第 二次会议于 2025 年 7 月 22 日以现场结合通讯会议的方式召开。本次会议为紧急 会议，经全体董事一致同意豁免本次会议通知的期限要求，并已在董事会会议上 就豁免通知时限的相关情况做出说明。会议应到董事 9 人，实到董事 9 人，公司 高级管理人员列席了本次董事会。本次会议由董事长潘讴东先生主持，会议的召 集和召开符合《中华人民共和国公司法》等有关法律法规及《和元生物技术（上 海）股份有限公司章程》的规定。 二、董事会会议审议情况 本议案已经公司第四届董事会薪酬与考核委员会第二次会议审议通过。 关联董事潘讴东先生、王富杰先生、殷珊女士、潘俊屹先生、宋思杰先生回 避表决。 (一) 审议通过《关于向 2025 ...

Core Viewpoint - The gene sequencing sector has shown a modest increase of 0.44%, ranking fifth among concept sectors, with notable performances from stocks like Nanjing Xinbai and Zhaoyan New Drug [1][2]. Market Performance - The gene sequencing concept saw 29 stocks rise, with Nanjing Xinbai hitting the daily limit up, and other top gainers including Heyuan Biological and Qianyuan Pharmaceutical, which rose by 8.61%, 6.96%, and 6.43% respectively [1]. - Conversely, stocks like Puni Testing, Zhongyuan Co., and Betta Pharmaceuticals experienced declines of 3.73%, 2.71%, and 2.46% respectively [1]. Capital Flow - The gene sequencing sector attracted a net inflow of 122 million yuan, with 34 stocks receiving net inflows, and 8 stocks exceeding 30 million yuan in net inflow [2]. - Zhaoyan New Drug led the sector with a net inflow of 203 million yuan, followed by Nanjing Xinbai and Qianyuan Pharmaceutical with net inflows of 111 million yuan and 64.63 million yuan respectively [2]. Capital Inflow Ratios - Nanjing Xinbai, Zhaoyan New Drug, and Heyuan Biological had the highest net inflow ratios at 43.57%, 12.72%, and 10.88% respectively [3].

Core Viewpoint - He Yuan Bio disclosed a research meeting with investors, highlighting its focus on domestic clients and the growth in the cell and gene therapy sector despite challenges in the broader healthcare financing landscape [1][2]. Company Overview - He Yuan Bio hosted an event titled "I am a Shareholder - Walk into the Listed Company" on July 18, 2025, attended by over 10 investors [2]. - The company is led by key personnel including Chairman and General Manager Pan Oudong, and other executives participated in the discussions [1]. Financial Performance - In 2024, the company achieved revenue of 248.15 million yuan, a year-on-year increase of 21.16%, with specific growth in CRO and CDMO segments [4]. - For Q1 2025, revenue was 52.85 million yuan, a decline of 11.29% compared to the previous year, primarily due to a drop in CDMO revenue [4]. Client Distribution - The company primarily serves domestic clients, with plans to expand its CRO services to pharmaceutical enterprises and enhance its international presence in the CDMO sector [3]. Data Security Measures - He Yuan Bio emphasizes data security, having achieved ISO27001 certification and implementing robust data management and protection systems [5]. CDMO Dependency - The company noted that the complexity of new drug development increases reliance on CDMO services, with over 65% of gene therapy companies outsourcing production [6]. Competitive Advantages - He Yuan Bio possesses a comprehensive CRO/CDMO technology platform, advanced GMP production facilities, and a strong project management capability, which collectively enhance its competitive edge in the cell and gene therapy market [6][7][8]. Cash Flow Situation - In 2024, the company reported a net cash flow of -218.09 million yuan, with ongoing challenges in cash flow due to extended payment cycles from clients [9]. - As of Q1 2025, the company continued to experience negative cash flow but anticipates improvement with the recovery of the investment environment [9]. Accounts Receivable and Bad Debt - As of December 31, 2024, the company had accounts receivable of 85 million yuan, with a bad debt provision of 6.96 million yuan, indicating a low risk of bad debts due to a strong client base [9]. Market Trends - In H1 2025, global healthcare financing decreased by 10%, while financing in China's cell and gene therapy sector increased to approximately 409 million USD, reflecting a recovery in this niche market [9].

Core Viewpoint - The company has conducted a self-examination regarding the trading activities of insiders and incentive recipients related to its 2025 restricted stock incentive plan, confirming no violations of insider trading regulations [1][2][3] Group 1: Incentive Plan Overview - The company announced its 2025 restricted stock incentive plan on June 28, 2025, and disclosed relevant proposals on the Shanghai Stock Exchange [1] - The incentive plan is governed by the "Management Measures for Equity Incentives of Listed Companies" and other relevant regulations [2] Group 2: Self-Examination Process - The company implemented necessary confidentiality measures and registered insiders and incentive recipients as per legal requirements [2] - A thorough investigation was conducted to verify if any insider or incentive recipient traded the company's stock within six months prior to the announcement of the incentive plan [2] Group 3: Findings and Conclusions - The examination revealed that no insider or incentive recipient engaged in trading the company's stock during the self-examination period [3] - All actions of the examined parties were found to be in compliance with the relevant regulations, confirming no insider trading occurred [3]

Meeting Overview - The shareholders' meeting of He Yuan Biotechnology (Shanghai) Co., Ltd. was held on July 16, 2025, in Shanghai [1] - A total of 141 ordinary shareholders attended the meeting, holding 242,506,848 voting rights, which accounts for 38.4742% of the company's total voting rights [1] Voting Results - All proposed resolutions were passed with significant majority support, including: - The first resolution received 66,747,500 votes in favor, representing 98.1783% of the votes [1] - The second resolution received 66,746,800 votes in favor, representing 98.1773% of the votes [1] - The third resolution received 66,746,800 votes in favor, representing 98.1773% of the votes [1] Legal Compliance - The meeting was convened in accordance with the Company Law and the company's articles of association, with the chairman presiding over the meeting [1][2] - The legal representatives confirmed that the meeting's procedures complied with relevant laws and regulations, ensuring the legitimacy of the resolutions passed [2][3]

根据《上市公司股权激励管理办法》（以下简称"《管理办法》"）《上市公 司信息披露管理办法》等法律、法规和规范性文件以及公司《内幕信息知情人登 记管理制度》的规定，公司对 2025 年限制性股票激励计划（以下简称"本次激 励计划"）采取了充分必要的保密措施，并对本次激励计划的内幕信息知情人及 激励对象进行了登记，通过向中国证券登记结算有限责任公司上海分公司查询， 公司对内幕信息知情人及激励对象在本次激励计划公告前 6 个月内（即 2024 年 12 月 28 日至 2025 年 6 月 27 日，以下简称"自查期间"）买卖公司股票的情况 进行了自查，具体情况如下： 证券代码：688238 证券简称：和元生物 公告编号：2025-053 和元生物技术（上海）股份有限公司 关于公司 2025 年限制性股票激励计划 内幕信息知情人及激励对象买卖公司股票情况的自查报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 和元生物技术（上海）股份有限公司（以下简称"公司"）于 2025 年 6 月 27 日召开了第四届董事会第一次会议，审 ...